Unknown

Dataset Information

0

High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.

ABSTRACT: In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not performed, yet 27% of individuals with viral failure at week 48 experienced resuppression by week 96 without switching. This supports World Health Organization recommendations that suspected viral failure should trigger adherence counseling and repeat measurement before a treatment switch is considered.

SUBMITTER: Gupta RK 

PROVIDER: S-EPMC3952602 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.

Gupta Ravindra K RK   Goodall Ruth L RL   Ranopa Michael M   Kityo Cissy C   Munderi Paula P   Lyagoba Fred F   Mugarura Lincoln L   Gilks Charles F CF   Kaleebu Pontiano P   Pillay Deenan D  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20131218 7

In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not performed, yet 27% of individuals with viral failure at week 48 experienced resuppression by week 96 without switching. This supports World Health Organization recommendations that suspected viral failure should trigger adherence counseling and repeat measurement before a treatment switch is considered. ...[more]

Similar Datasets

Unknown Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
| S-EPMC6641111 | biostudies-literature
Unknown Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data.
| S-EPMC4672690 | biostudies-literature
Unknown Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.
| S-EPMC5519043 | biostudies-literature
Unknown Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
| S-EPMC3923537 | biostudies-literature
Unknown Positive Predictive Value of the WHO Clinical and Immunologic Criteria to Predict Viral Load Failure among Adults on First, or Second-Line Antiretroviral Therapy in Kenya.
| S-EPMC4934908 | biostudies-literature
Unknown Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
| S-EPMC4043936 | biostudies-literature
Unknown Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
| S-EPMC7494118 | biostudies-literature
Unknown Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
| S-EPMC5796645 | biostudies-literature
Unknown Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India.
| S-EPMC6820927 | biostudies-literature
Unknown Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
| S-EPMC4352713 | biostudies-literature